While reports indicate little IL6 production from primary or metastatic clinical prostate cancer samples, the IL6 receptor is present uniformly in a majority of prostate cancers (Siegall et al, 1990; Culig, 2014; Yu et al, 2015). Here, IL6 is linked to prostate carcinoma.